Cellectis
CLLS
$2.46
Share price
-1.99%
Change (1 day)
20.59%
Change (1 year)
Categories
Earnings for Cellectis (CLLS)
Earnings in 2023 (TTM): -$66.01 M
According to Cellectis's latest financial reports the company's current earnings (TTM) are -$66.01 M. In 2022 the company made an earning of -$86 M an increase over its 2021 earnings that were of -$0.13 B.The earnings displayed on this page is the company's Pretax Income.
Earnings history for Cellectis from 2015 to 2023
Annual earnings
| Year | Earnings | Change |
|---|---|---|
| 2023 (TTM) | -$66.01 M | -23.25% |
| 2022 | -$86 M | -31.26% |
| 2021 | -$0.13 B | 27.21% |
| 2020 | -$98.35 M | -14.62% |
| 2019 | -$0.12 B | 30.34% |
| 2018 | -$88.38 M | -15.02% |
| 2017 | -$0.11 B | 62.17% |
| 2016 | -$64.13 M | 185.48% |
| 2015 | -$22.47 M |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Regeneron Pharmaceuticals REGN | $4.19 B | -6,461.80% | 🇺🇸 USA |
 uniQure QURE | -$0.31 B | 364.42% | 🇳🇱 Netherlands |
 Novavax NVAX | -$0.53 B | 700.83% | 🇺🇸 USA |
 Flexion Therapeutics
FLXN | -$79.39 M | 20.27% | 🇺🇸 USA |